drugset / Trial / NCT00954304
Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet
RandomizedParallel-groupOpen-labelTreatment
Summary
The purposes of this study are to investigate the duration of P-glycoprotein inhibition after oral administration of HM30181AK tablet in healthy male subject and proper dose of HM30181AK tablet.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-08
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM30181AK | Unknown | 1 mg | Oral |
| Subject | HM30181AK | Unknown | 5 mg | Oral |
| Subject | HM30181AK | Unknown | 10 mg | Oral |
| Subject | HM30181AK | Unknown | 15 mg | Oral |
| Subject | HM30181AK | Unknown | 60 mg | Oral |
| Background | Loperamide | Small molecule | 2 mg | — |
Indications
No indication recorded.